Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Astracytron Extra is an over-the-counter (OTC) fixed-dose combination medication developed and manufactured by Astrapharm for the symptomatic relief of acute respiratory viral infections (ARVI) and influenza. It contains four active ingredients: paracetamol (an analgesic and antipyretic), phenylephrine hydrochloride (a decongestant), pheniramine maleate (an antihistamine), and ascorbic acid (vitamin C). Together, these components work synergistically to reduce fever, alleviate headaches and muscle aches, relieve nasal congestion, and support the immune system during viral infections. The drug is formulated as a powder for oral solution in sachets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ascorbic acid + paracetamol + pheniramine + phenylephrine.